All studies
RecruitingPHASE2INTERVENTIONAL

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

Chronic obstructive pulmonary disease (COPD) causes breathing difficulties, chest tightness, and coughing. The main treatment usually combines two types of medicines that relax and widen the airways. These are normally taken through handheld inhalers. However, many people—especially older adults—find handheld inhalers tricky to use properly and do not get the full dose. This trial is looking at AERO-007, an experimental treatment that combines these two medicines into a liquid. Patients breathe it in as a fine mist through an ordinary nebuliser machine. This would be the first time both medicines are offered together in a nebuliser. The main aim of this Phase 2 study is to test different doses over two-week periods to see which works best and how safe it is. Participants must be aged 40 to 75 with a confirmed COPD diagnosis of at least one year.

At a glance

Status
Recruiting
Phase
PHASE2
Sponsor
AeroRx Therapeutics Inc.
Enrolment target
64
Start
01 Nov 2026
Estimated completion
01 Sep 2027

What is this study about?

Chronic obstructive pulmonary disease, or COPD, is a long-term lung condition that makes it difficult to move air in and out of the lungs. For many people, the best first-line treatment is a combination of two medicines: a long-acting beta-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). Working together, these drugs relax the muscles around the airways, making breathing noticeably easier throughout the day.

Currently, these medicines are only combined in handheld inhalers, such as aerosol puffers or dry powder devices. While these work well for many, they require good coordination and enough breathing strength to pull the medicine deep into the lungs. Many people, particularly older individuals or those who are frail, struggle to use them effectively and miss out on the full benefit of their treatment.

A nebuliser offers a helpful alternative. Instead of requiring a sharp, coordinated breath in, a nebuliser machine turns liquid medicine into a steady, gentle mist that you simply inhale through a mouthpiece or mask. At present, there is no approved treatment that combines both of these key medicines in a single nebuliser liquid. AERO-007 is designed to fill this gap.

In an earlier early-stage study, AERO-007 was well tolerated and helped open patients' airways for up to 24 hours. This new Phase 2b trial takes the next step. Researchers want to test different dose strengths over 14-day periods to find the safest and most effective dose, helping to pave the way for a practical new COPD treatment.

Key takeaways

  • Tests a two-in-one COPD medicine delivered through a nebuliser rather than a handheld puffer.
  • Aims to help people who have difficulty getting the full benefit from standard inhalers.
  • Open to adults aged 40 to 75 who have had COPD for at least one year and have a smoking history.
  • Involves taking the medicine over two 14-day periods alongside regular clinic health checks.
  • Taking part is completely voluntary and you can stop at any time without changing your usual care.

Who may be eligible?

This study is open to men and women aged 40 to 75 who have had a confirmed clinical diagnosis of COPD for at least 12 months. Because smoking is the leading cause of COPD, participants must be current or former smokers with a history of at least 10 'pack-years' (for example, smoking one pack of 20 cigarettes a day for 10 years, or two packs a day for 5 years).

To ensure the study is safe and appropriate for you, your lung capacity will be tested using a simple breathing test called spirometry. Your results must fall within a moderate range of lung narrowing, and your breathing must show a clear, measurable improvement after taking a standard reliever medicine puff.

You will need to be able to temporarily pause your regular long-acting COPD medicines during the study, as well as avoid short-acting relievers for eight hours before study visits (safe alternative relief medicine is provided). Women who can have children and sexually active men must use reliable contraception throughout the trial, and women must not be pregnant or breastfeeding.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you between 40 and 75 years of age?
  2. Have you been diagnosed with COPD for at least 12 months?
  3. Are you a current or former smoker with a regular smoking history?
  4. Are you comfortable performing routine lung-function breathing tests?
  5. Are you willing to pause your usual long-acting inhalers under medical supervision?
Answer every question to see your result.

What does participation involve?

Taking part involves several stages over a few months. First, you will attend screening visits where the study team will review your medical history, perform lung function tests, and check your general health to ensure the trial is safe for you. If you join, you will take part in two separate 14-day treatment periods. During these times, you will take the study medicine once a day using a standard nebuliser at home or at the clinic. Because this is a crossover study, you may receive different doses or a dummy medicine (placebo) at different times so researchers can make a fair comparison. You will visit the clinic regularly for breathing tests, blood checks, and health reviews. The study team will provide emergency rescue inhalers to use if your symptoms flare up, and they will check on your recovery after the treatment periods finish.

Potential risks and benefits

You may experience better breathing while taking the study medicine, and your involvement could help improve future treatment options for people who struggle with standard inhalers. However, there is no guarantee of personal health benefit. As with any medicine, there is a risk of side effects, which may include a dry mouth, mild shakiness, or a rapid heartbeat. Pausing your usual daily inhalers could also cause a temporary flare-up in your symptoms, although rescue medication will always be available. Taking part is completely voluntary. You are free to withdraw from the trial at any time, for any reason, and your regular NHS medical care will not be affected.

Locations (2)

  • Parexel
    Verified postcode
    London, United Kingdom· Recruiting
  • Medicines Evaluation Unit
    Verified postcode
    Manchester, United Kingdom· Recruiting

Common questions

What is a nebuliser and how does it work?

A nebuliser is a small machine that converts liquid medicine into a fine, breathable mist. You simply put on a mask or use a mouthpiece and breathe normally until the medicine is finished.

Will I have to stop taking my usual COPD medicines?

Yes. To see how well the study drug works on its own, you will need to pause your routine long-acting inhalers. The study team will closely monitor you and provide fast-acting rescue medicine if your symptoms worsen.

What is a placebo and might I receive one?

A placebo is an inactive substance that looks just like the real medicine. In this trial, some treatments may include a placebo to help doctors prove that the improvements are genuinely caused by the active drug.

Does it cost anything to take part?

No. All study medication, nebuliser equipment, and clinic visits are provided free of charge. Most trials also help cover reasonable travel expenses to and from the clinic.

Can I leave the study early if I find it too difficult?

Yes. You can leave the study at any point without giving a reason. Your doctors will simply switch you back to your normal COPD treatment plan.

How to find out more

Study Director Medical Director

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled L…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.